Pharmacoeconomic review report. AbobotulinumtoxinA (Dysport therapeutic) (Ipsen Biopharmaceuticals Canada, Inc.).
AbobotulinumtoxinA (aboBoNTA, Dysport Therapeutic) is a botulinum neurotoxin subtype indicated to reduce the subjective symptoms and objective signs of cervical dystonia (CD, spasmodic torticollis) in adults, and is available in single-use vials of 300 U and 500 U at submitted prices of $428.40 and...
Saved in:
| Online Access: |
http://www.ncbi.nlm.nih.gov/books/NBK535069/ Full text |
|---|---|
| Format: | Electronic eBook |
| Language: | English |
| Published: |
Ottawa (ON) :
Canadian Agency for Drugs and Technologies in Health,
2017
|
| Series: | Common drug review clinical review report.
|
| Subjects: |
MARC
| LEADER | 00000cam a2200000 i 4500 | ||
|---|---|---|---|
| 001 | p2436907 | ||
| 005 | 20240212122442.0 | ||
| 006 | m o d | ||
| 007 | cr cn |||||||| | ||
| 008 | 190102s2017 onca ob 000 0 eng | ||
| 035 | |a (DNLM)BKSHLF:NBK535069 | ||
| 035 | |9 101740873 | ||
| 035 | |a 1740873 | ||
| 040 | |a DNLM |b eng |e rda |c DNLM |d UtOrBLW | ||
| 041 | 0 | 9 | |a eng |
| 042 | |a pcc | ||
| 043 | |a n-cn--- | ||
| 044 | |9 Canada | ||
| 060 | 0 | 0 | |a WE 708 |
| 245 | 0 | 0 | |a Pharmacoeconomic review report. |p AbobotulinumtoxinA (Dysport therapeutic) (Ipsen Biopharmaceuticals Canada, Inc.). |
| 246 | 1 | |a Pharmacoeconomic review report for Dysport therapeutic | |
| 246 | 1 | |a AbobotulinumtoxinA (Dysport therapeutic) (Ipsen Biopharmaceuticals Canada, Inc.) | |
| 264 | 1 | |a Ottawa (ON) : |b Canadian Agency for Drugs and Technologies in Health, |c August 2017. | |
| 300 | |a 1 online resource (1 PDF file (16 pages)) : |b illustrations. | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 490 | 1 | |a CADTH common drug review | |
| 500 | |a "Version: Final." | ||
| 504 | |a Includes bibliographical references. | ||
| 520 | 3 | |a AbobotulinumtoxinA (aboBoNTA, Dysport Therapeutic) is a botulinum neurotoxin subtype indicated to reduce the subjective symptoms and objective signs of cervical dystonia (CD, spasmodic torticollis) in adults, and is available in single-use vials of 300 U and 500 U at submitted prices of $428.40 and $714.00, respectively. The recommended initial dose of aboBoNTA is 500 U intramuscularly as a divided dose among affected muscles in patients with and without a prior history of treatment with botulinum toxin. Re-treatment of 250 U to 1,000 U divided among affected muscles is recommended when the effect of a previous injection has diminished, but no sooner than 12 weeks after the previous injection. The manufacturer is requesting that aboBoNTA be reimbursed in line with its indication. | |
| 536 | |a Funding: CADTH receives funding from Canada's federal, provincial, and territorial governments, with the exception of Quebec. | ||
| 588 | |a Description based on online resource; title from PDF title page (viewed February 21, 2019). | ||
| 650 | 1 | 2 | |a Torticollis |x drug therapy. |0 D014103Q000188 |
| 650 | 2 | 2 | |a Botulinum Toxins, Type A |x therapeutic use. |0 D019274Q000627 |
| 650 | 2 | 2 | |a Cost-Benefit Analysis. |0 D003362 |
| 651 | 2 | |a Canada. |0 D002170 | |
| 710 | 2 | |a Canadian Agency for Drugs and Technologies in Health, |e issuing body. |0 n 2007182676 | |
| 830 | 0 | |a Common drug review clinical review report. |0 n 2014186107 | |
| 856 | 4 | 0 | |u http://www.ncbi.nlm.nih.gov/books/NBK535069/ |t 0 |
| 951 | |a 2436907 | ||
| 992 | |p P2 |e EF |a 20190102 | ||
| 993 | |a KXP |b 20190212 | ||
| 995 | |a AUTH |b 20190221 |c REV |d 20190227 | ||
| 998 | |a BKSHLF |b 20190102 | ||
| 998 | |a FER |b 20190102 | ||
| 999 | |a AUTH | ||
| 999 | f | f | |i 9f2435fa-d6ca-5998-b976-2b1300736081 |s d1ae0ace-8aa1-5cec-bed4-7b274a2bbc63 |t 0 |
| 952 | f | f | |a Massachusetts College of Pharmacy and Health Sciences |b Online |c Online |d E-Collections |t 0 |e NCBI |h Other scheme |
| 856 | 4 | 0 | |t 0 |u https://www.ncbi.nlm.nih.gov/books/NBK535069/ |y Full text |
